What is the normal neutrophil-to-lymphocyte ratio in systemic lupus erythematosus and how is it used to assess disease activity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Neutrophil-to-Lymphocyte Ratio in Systemic Lupus Erythematosus

The neutrophil-to-lymphocyte ratio (NLR) is NOT included in established guidelines for monitoring SLE disease activity, and while research shows it correlates weakly with disease activity, it should not be used as a standalone marker but only as an adjunctive tool alongside standard serological markers (anti-dsDNA, complement levels) and validated disease activity indices (SLEDAI, SLE-DAS).

What the Guidelines Actually Recommend

The EULAR recommendations for monitoring SLE patients 1 and the 2023 expert panel on anti-dsDNA antibodies 2 make no mention of NLR as a monitoring parameter. Instead, they emphasize:

  • Anti-dsDNA antibodies and complement levels (C3, C4) for monitoring disease activity
  • Complete blood counts focusing on severe leucopenia and lymphopenia (≤1×10⁹/L) as markers of infection risk 1
  • Validated disease activity indices: SLEDAI, SLE-DAS, BILAG, or PGA 2
  • Organ-specific markers: proteinuria, creatinine, urinalysis for renal involvement 1

The guidelines specifically note that severe lymphopenia is associated with infection occurrence, not disease activity per se 1.

What the Research Shows About NLR

Normal Values and Cut-offs

Research studies have proposed various NLR cut-off values, but with significant variability:

  • 2.94 (sensitivity 60.7%, specificity 76.8%) 3
  • 3.11 (sensitivity 55.6%, specificity 68.7%) 4
  • 2.26 (sensitivity 75%, specificity 50%) 5
  • 1.93 (sensitivity 70%, specificity 67%) 6

The most recent meta-analysis 7 found NLR is elevated in SLE patients versus healthy controls (SMD = 1.051), but another 2026 meta-analysis 8 revealed that after adjusting for publication bias, the correlation between NLR and SLEDAI drops to only r = 0.200, indicating a weak relationship.

Clinical Performance

The evidence reveals significant limitations:

  • NLR shows only weak positive correlation with SLEDAI scores (r = 0.330 unadjusted, r = 0.200 adjusted for bias) 8
  • Discriminatory accuracy is limited (AUC 0.668-0.757) 8
  • The 2025 study 4 found NLR correlated with SLE-DAS (rho 0.17), but this is a very weak correlation
  • NLR was significantly higher in patients with active renal disease 4, 5, but the 2026 meta-analysis 7 found no significant difference between active lupus nephritis and non-LN groups (p = 0.074)

Major Confounders

Critical pitfalls to recognize:

  • Ethnicity significantly affects NLR values 7, 8
  • Immunosuppressive treatments alter NLR, making interpretation unreliable 8
  • Infections dramatically elevate NLR, and SLE patients are at high risk for infections, especially with lymphopenia 1
  • Corticosteroid therapy affects both neutrophil and lymphocyte counts independently of disease activity

Practical Clinical Approach

For assessing SLE disease activity, use this algorithm:

  1. Primary assessment tools (as per guidelines):

    • Anti-dsDNA antibodies (quantitative assay, same method/lab) 2
    • Complement levels (C3, C4)
    • Complete blood count (looking for cytopenias)
    • Validated disease activity index (SLEDAI-2K or SLE-DAS)
    • Organ-specific markers (proteinuria, creatinine for renal involvement)

  2. If considering NLR as adjunctive information:

    • Calculate NLR only in untreated or stable treatment patients
    • Exclude active infection first (check CRP >50 mg/L suggests infection 1)
    • Use NLR >3.0 as a rough threshold suggesting possible increased activity
    • Never use NLR alone to guide treatment decisions
    • Recognize that normal NLR does not exclude active disease

  3. When NLR may have limited utility:

    • Patients on high-dose corticosteroids (>20 mg/day)
    • Recent changes in immunosuppressive therapy
    • Any clinical suspicion of infection
    • Patients with known chronic lymphopenia

Key Caveats

The fundamental problem: NLR is a non-specific inflammatory marker that reflects the balance between innate and adaptive immunity, but in SLE this balance is affected by disease activity, treatment, infections, and individual patient factors simultaneously. The weak correlation with validated disease activity measures (r = 0.200) 8 means that for any individual patient, NLR provides minimal additional information beyond what standard monitoring already captures.

Bottom line: While NLR is elevated in active SLE and shows statistical associations in research cohorts, its clinical utility for individual patient management is severely limited by poor discriminatory accuracy, treatment effects, and confounding by infections. Stick to guideline-recommended monitoring parameters that have proven clinical validity.

References

Related Questions

What is the clinical significance of an elevated neutrophil-to-lymphocyte ratio of 3.3, and how should it be evaluated and managed when it is the only abnormal laboratory finding aside from cholesterol?
Should antibiotics be prescribed for a swollen finger laceration with clear drainage and pain on movement sustained while gutting deer meat?
What is the recommended evaluation and management for an adult with acute or chronic ankle joint or plantar fascia disorders?
Is indapamide appropriate as first-line therapy for arterial hypertension in adults, and what are the recommended dosage, contraindications, and monitoring requirements?
Which specialist(s) should I refer a patient with unilateral lower extremity edema, ipsilateral inguinal lymphadenopathy, knee pain, and club‑foot deformity to?
What is an appropriate tapering schedule for a patient who has been taking Zopiclone 7.5 mg orally every night at bedtime for five years?
How should I manage a patient who is currently taking olanzapine and hydroxyzine as needed (prn)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.